Dr. Victor Y. Yazbeck
Claim this profileVirginia Commonwealth University/Massey Cancer Center
Studies Lymphoma
Studies Hodgkin's Lymphoma
9 reported clinical trials
20 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
CCND1 positive
2Hodgkin's Lymphoma
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Victor Y. Yazbeck is currently running
AB-101 + Immunotherapy
for Non-Hodgkin's Lymphoma
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Recruiting1 award Phase 1 & 24 criteria
Pirtobrutinib + VR
for Chronic Lymphocytic Leukemia
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Recruiting2 awards Phase 3
More about Victor Y. Yazbeck
Clinical Trial Related11 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Victor Y. Yazbeck has experience with
- Brentuximab Vedotin
- Rituximab
- Venetoclax
- Cyclophosphamide
- Doxorubicin
- Prednisone
Breakdown of trials Victor Y. Yazbeck has run
Lymphoma
Hodgkin's Lymphoma
T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Victor Y. Yazbeck specialize in?
Victor Y. Yazbeck focuses on Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Victor Y. Yazbeck currently recruiting for clinical trials?
Yes, Victor Y. Yazbeck is currently recruiting for 3 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Victor Y. Yazbeck has studied deeply?
Yes, Victor Y. Yazbeck has studied treatments such as Brentuximab Vedotin, Rituximab, Venetoclax.
What is the best way to schedule an appointment with Victor Y. Yazbeck?
Apply for one of the trials that Victor Y. Yazbeck is conducting.
What is the office address of Victor Y. Yazbeck?
The office of Victor Y. Yazbeck is located at: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298 United States. This is the address for their practice at the Virginia Commonwealth University/Massey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.